Top Markets
Coin of the day
Achilles Therapeutics plc Achilles Therapeutics plc

Achilles Therapeutics plc

ACHL
Rang in Aktien #24575
Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused... Achilles Therapeutics Plc is a clinical-stage biopharmaceutical company focused on immuno-oncology. The firm specializes in creating innovative precision T-cell therapies designed to combat a range of solid tumors. Its primary therapeutic candidates, both currently undergoing Phase I/IIa clinical trials, are CHIRON, aimed at advanced non-small cell lung cancer, and THETIS, targeting metastatic or recurrent melanoma. Beyond these, Achilles is also advancing its pipeline with treatments for head and neck squamous cell carcinoma, renal cell carcinoma, triple-negative breast cancer, and bladder cancer. Initially incorporated as Achilles TX Limited, the company officially adopted the name Achilles Therapeutics Plc in February 2021. Established in 2016, its corporate headquarters are situated in London, United Kingdom.
Aktienkurs
$1.48
Zuletzt synchronisiert: 2025-03-24
Marktkapitalisierung
$59.05M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
GB
Handel Achilles Therapeutics plc (ACHL)

Kategorie

Dividendenrendite-Verlauf für Achilles Therapeutics plc (ACHL)
Dividendenrendite (TTM) von Achilles Therapeutics plc (Aktienkürzel: ACHL) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Achilles Therapeutics plc (ACHL) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
Unternehmen Dividendenrendite Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH